[A24-104] Pembrolizumab (TNBC, neoadjuvant and adjuvant) – Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Last updated 02.01.2025
Project no.: A24-104
Commission: Commission awarded on 30.09.2024 by the Federal Joint Committee (G-BA).
Report type: Dossier assessment
Status: Commission completed
Department/Division: Drug Assessment
Topic: Cancer
Adult patients with locally advanced, or early-stage triple-negative breast cancer at high risk of recurrence, in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery
- Patients for whom paclitaxel + carboplatin followed by doxorubicin or epirubicin + cyclophosphamide is the suitable neoadjuvant chemotherapy of physician’s choice: hint of minor added benefit
- Patients for whom paclitaxel + carboplatin followed by doxorubicin or epirubicin + cyclophosphamide is not the suitable neoadjuvant chemotherapy of physician’s choice: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A24-104_en